SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- In collaboration with leading medical researchers from around the world, ResMed (RMD) presented 13 new clinical studies at SLEEP 2024, the annual joint ...

The utilization of positive airway pressure (PAP) therapy is associated with reduced rates of mortality and incidence of major adverse cardiovascular events (MACEs) in older adults with obstructive ...

New findings show positive airway pressure (PAP) therapy reduced risks of death and hospitalization for patients with obstructive sleep apnea (OSA) Prevalence of OSA in the United States expected to ...

Please provide your email address to receive an email when new articles are posted on . Researchers pooled together randomized controlled trials and non-randomized controlled studies reporting on CPAP ...

Auto-titrating continuous positive airway pressure, or AutoCPAP therapy, is useful for the treatment of obstructive sleep apnea. It is delivered via a face mask and tubing that attaches to a device ...

Please provide your email address to receive an email when new articles are posted on . Adults with OSA and obesity receiving tirzepatide had reductions in apnea-hypopnea index events and body weight.

SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) launched today its AirCurve 11 series devices, the company’s newest bilevel devices that use two levels of support, ...

A new study shows that positive airway pressure (PAP) therapy for sleep apnea may have a positive impact on sleep-related functional outcomes among patients who also suffer from hypertension. The ...

ResMed studies presented at SLEEP 2024 also revealed a 17% prevalence of insomnia among adults in North America, Latin America, and the Caribbean, and a higher rate of depression in women with OSA SAN ...